Fast-Tracking Drug Substance Development with AI, HTE, and Digital Twins

Abstract

The increasing structural complexity of active pharmaceutical ingredients (APIs) poses significant challenges for early-phase drug substance development, where speed and reliability are critical for clinical readiness. To address these limitations, we present an integrated, technology-driven framework combining AI-enabled route scouting, high-throughput experimentation (HTE), model-based process optimization (Design2Optimize^TM) and AI-assisted co-crystal prediction. Case studies demonstrating substantial benefits, including reductions in synthetic step count, material consumption, experimental effort, and overall development time will be discussed. This integrated approach de-risks early-phase development, supports more sustainable development practices, and enables strategic decision-making, offering a paradigm shift toward faster, smarter, and more resilient drug substance development.